Second NIH Symposium on Therapeutic Oligonucleotides, Bethesda, Maryland, USA, 5 December 1997: An overview of progress in antisense therapeutics

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 2, 1998, Pages 115-122

  Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; NUCLEOTIDE;

CONFERENCE PAPER; PRIORITY JOURNAL; ANIMAL; BIOAVAILABILITY; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; FORECASTING; GENE EXPRESSION REGULATION; GENE THERAPY; HALF LIFE TIME; HAPLORHINI; HUMAN; LD 50; REVIEW; RODENT; SPECIES DIFFERENCE;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION ROUTES; FORECASTING; GENE EXPRESSION REGULATION; GENE THERAPY; HALF-LIFE; HAPLORHINI; HUMANS; LETHAL DOSE 50; OLIGONUCLEOTIDES, ANTISENSE; RODENTIA; SPECIES SPECIFICITY; THIONUCLEOTIDES;

EID: 0032044068     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.115     Document Type: Conference Paper

References (10)

1. AGRAWAL, S., TEMSAMANI, J., and TANG, J.Y. (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599.
2. AGRAWAL, S., ZHANG, X., LU, Z., ZHAO, H., TAMBURIN, J.M., VAN, J., CAT, H., DIASIO, R.B., HABUS, I., JIANG, Z., IYER, R.P., YU, D., and ZHANG, R. (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50, 571-576.
3. BAYEVER, E., IVERSEN, P.L., BISHOP, M.R., SHARP, J.G., TEWARY, H.K., ARNESON, M.A., PIRRUCCELLO, S.J., RUDDON, R.W., KESSINGER, A., and ZON, G. (1993). Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial. Antisense Res. Dev. 3, 383-390.
4. BENNETT, C.F., CHIANG, M.-Y., CHAN, H., and GRIMM, S. (1993). Use of cationic lipids to enhance the biological activity of antisense oligonucleotides. J. Liposome Res. 3, 85-102.
5. BENNETT, C.F., CHIANG, M.-Y., CHAN, H., SHOEMAKER, J.E.E., and MIRABELLI, C.K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033.
6. TAKAKURA, Y., MAHATO, R.I., YOSHIDA, M., KANAMARU, T., and HASHIDA, M. (1996). Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucleic Acid Drug Dev. 6, 177-183.
7. TAO, L.F., MARX, K.A., WONGWTT, W., JIANG, Z., AGRAWAL, S., and COLEMAN, R.M. (1995). Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by Schistosoma mansoni. Antisense Res. Dev. 5, 123-129.
8. WANG, S., LEE, R.J., CAUCHON, G., GORENSTEIN, D.G., and LOW, P.S. (1995). Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA 92, 3318-3322.
9. WICKSTROM, E. (1986). Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13, 97-102.
10. ZHANG, R., VAN, J., SHAHINIAN, H., AMIN, G., LU, Z., LIU, T., SAAG, M.S., JIANG, Z., TEMSAMANI, J., MARTIN, R.R., SCHECHTER, P.J., AGRAWAL, S., and DIASIO, R.B. (1995). Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58, 44-53.